Chemed Corp: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 4, 2019 and accepted by EDGAR at Nov 4, 2019, 08:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $480.6m | us-gaap:Revenues |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $1.42bn | us-gaap:Revenues |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $328.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $973.8m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2019-07-01 to 2019-09-30 | $76.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2019-01-01 to 2019-09-30 | $222.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | $64.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | $179.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | $1.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-30 | $3.4m | us-gaap:InterestExpense |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $8.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $27.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | $58.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | $154.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | $3.56 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | $9.35 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | $3.69 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | $9.68 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-07-01 to 2019-09-30 | 16,555,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-30 | 16,514,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | $237.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $39.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2019-01-01 to 2019-09-30 | $14.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months2019-01-01 to 2019-09-30 | $71.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-09-30 | $9.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $167.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $1.23bn | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $251.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $560.2m | us-gaap:Liabilities |
| Long-term debt | At period end2019-09-30 | $130.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2019-09-30 | $672.4m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2019-09-30 | 16,009,258 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000019584-19-000016. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.